Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Sadly typical of Abingdon not to keep investors informed. These are comments from the recent update. They’ve consistently strung investors along for the last couple of years. I can’t find any evidence of Vatic selling a single test.
It is anticipated that there is the potential for significant manufacturing volume subject to Vatic attaining FDA EUA approval.
Just had a look at the interims from March. Abingdon very much gave the impression there was lots in pipeline but other than completion of TT for Vatic (which has gone quiet - production commencement comments appear to have been disingenuous) and the new website, we haven’t had a single meaningful update for six months.
How long can they stay quiet for?
I wasn’t angling for an ABDX ODX argument, however ODX had 2.6 million from memory without guarantee of the 4 million being paid. ABDX have more cash but neither scenario is great. I hope both companies turn it around and bloody quickly.
Feels like the management couldn’t give a toss here. Have another read of the business update. There are some encouraging bits going on in the background but it’s written like Armageddon’s just around the corner. Almost like they wanted to half the share price. Well at least they’ve done a good job of something.
The headlines we’ve seen associating Abingdon with VIP access must have caused reputational damage. I hope the court case outcome is positive and they go after the GLP for compensation.
Surprised there haven’t been more comments.
This is what really gets my goat with this company. How are they allows to continually get away with examples such as this.
April RNS
Abingdon has received initial purchase orders from Vatic for commercial sale, and manufacturing for these orders will now commence.
Most recent update.
Company continues to work closely with Vatic as they progress their US FDA Emergency Use Approval ("EUA") and awaits the key reagent from Vatic to begin the manufacturing of the devices
I didn’t like the wording regarding Vatic EUA which is why I think Taiwan is probably more important. Still no publication of the extended trail for knownow either.
It is anticipated that there is the potential for significant manufacturing volume subject to Vatic attaining FDA EUA approval; although the timing or materialisation of revenues in relation to this contract are uncertain.
Need the Taiwan deal for starters. Covid cases appear to be increasing there albeit slightly. Hard to imagine Abingdon not getting a single one of the announced contacts over the line.
Their communication to market needs to be seriously questioned.
Abingdon need to do something to support the share price. Almost 80% wiped off of the placing price now so needs to do 400% for investors to see their money back.
Surely one of their projects will come good. This is turning into a horror show.